scispace - formally typeset
F

Frederick P. Li

Researcher at Harvard University

Publications -  160
Citations -  18633

Frederick P. Li is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Wilms' tumor. The author has an hindex of 58, co-authored 160 publications receiving 18140 citations. Previous affiliations of Frederick P. Li include University of Colorado Denver & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

TL;DR: Germ line p53 mutations have been detected in all five LFS families analyzed and can now be examined in additional families with LFS, and in other cancer patients and families with clinical features that might be attributed to the mutation.
Journal ArticleDOI

Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?

TL;DR: A new "familial" syndrome of neoplastic diseases in which heredity or oncogenic agents, or both, may have a causal role is suggested.
Journal ArticleDOI

Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.

TL;DR: Keratinocyte replicative potential is limited by a p16INK4a-dependent mechanism, the activation of which can occur independent of telomere length, and abrogation of this mechanism together with telomerase expression immortalizes keratinocytes without affecting other major growth control or differentiation systems.
Journal ArticleDOI

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.

TL;DR: HCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and the central role of p53 inactivation in human cancer and the well-defined G2 checkpoint in yeast is provided.
Journal ArticleDOI

Bone sarcomas linked to radiotherapy and chemotherapy in children.

TL;DR: It is concluded that both radiotherapy and chemotherapy with alkylating agents for childhood cancer increase the subsequent risk of bone cancer.